Related Experiment Video
Updated: Aug 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm
Fei Fei1, Michaela Liedtke2, Oscar Silva1
1Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
Abstract:
Mature plasmacytoid dendritic cell proliferations (MPDCPs) are clonal, non-malignant pDC proliferations that have been reported to occur in association with myeloid neoplasms such as CMML, AML (pDC-AML), and, rarely, MDS or MPNs. Here we report the first case of a MPDCP associated with T-lymphoblastic leukemia (T-ALL), a lymphoid neoplasm. The MPDCP in this case involved ~50% of the bone marrow, was found in nodular aggregates, expressed CD123, CD4, and CD303, and lacked CD56 and TCL1 expression. In addition, the MPDCP lacked CD34 and TdT but showed aberrant expression of CD7, CD5, CD10, and CD13, markers expressed by the abnormal T-lymphoblastic cells. Mutational analysis demonstrated mutations in JAK3, NOTCH1, NRAS, KRAS, DNMT3A, and SH2B3 but no mutations in TET2, ASLX1 or ZRSR2. Analysis of the pDC frequency in a separate cohort of T-ALL and control patients demonstrated that bone marrow pDCs are often decreased in patients with T-ALL compared to controls. This is the first report of a MPDCP associated with a lymphoid neoplasm and provides further support that MPDCP can arise from a multipotent hematopoietic progenitor with lymphoid and dendritic cell potential.
Insights
Mature plasmacytoid dendritic cell proliferations (MPDCPs) are non-malignant clonal growths. This study reports the first MPDCP associated with T-lymphoblastic leukemia (T-ALL), a lymphoid neoplasm, expanding understanding of MPDCP origins.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Mature plasmacytoid dendritic cell proliferations (MPDCPs) are clonal, non-malignant growths typically associated with myeloid neoplasms.
- Previous reports have linked MPDCPs to conditions like CMML, AML, MDS, and MPNs.
Observation:
- This study details the first documented case of an MPDCP occurring in conjunction with T-lymphoblastic leukemia (T-ALL), a lymphoid neoplasm.
- The MPDCP comprised approximately 50% of the bone marrow, presenting in nodular aggregates with specific immunophenotypic markers (CD123, CD4, CD303) and aberrant expression of T-lymphoblastic markers (CD7, CD5, CD10, CD13).
Findings:
- Mutational analysis revealed mutations in JAK3, NOTCH1, NRAS, KRAS, DNMT3A, and SH2B3 in the MPDCP.
- Bone marrow plasmacytoid dendritic cell (pDC) frequency was often decreased in T-ALL patients compared to controls.
Implications:
- This case represents the first association of MPDCP with a lymphoid neoplasm, challenging previous associations solely with myeloid disorders.
- The findings suggest that MPDCPs may originate from multipotent hematopoietic progenitors with lymphoid and dendritic cell potential.
- Further research into MPDCPs in lymphoid neoplasms is warranted to understand their pathogenesis and clinical significance.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

